Clinical Trials | December 05, 2022
Jemperli RUBY phase III trial met its primary endpoint
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests
The joint venture will help both the parties to further develop the high-margin service business
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Subscribe To Our Newsletter & Stay Updated
